No Data
No Data
BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript
Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
Biolase Is Maintained at Speculative Buy by Benchmark
Biolase Is Maintained at Speculative Buy by Benchmark
Biolase Price Target Cut to $0.40/Share From $2.50 by Benchmark
Biolase Price Target Cut to $0.40/Share From $2.50 by Benchmark
Benchmark Maintains Speculative Buy on Biolase, Lowers Price Target to $0.4
Benchmark analyst Bruce Jackson maintains Biolase with a Speculative Buy and lowers the price target from $2.5 to $0.4.
Biolase Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 112.77% Benchmark $2.5 → $0.4 Maintains Speculative Buy 05/31/2023 112.77% Lake Street $1.5 → $
No Data